Treatment References

Alder, 2018a. Alder BioPharmaceuticals presents new 12-month data of eptinezumab in PROMISE 1 phase 3 trial showing long-term reduction in episodic migraine [press release]. 24 April 2018. Available from: http://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-presents-new-12-month-data-eptinezumab (accessed 08 June 2018).

Alder, 2018b. Alder announces eptinezumab significantly reduces migraine risk meets primary and all key secondary endpoints in pivotal PROMISE 2 phase 3 trial for chronic migraine prevention [press release]. 8 January 2018. Available from: http://investor.alderbio.com/news-releases/news-release-details/alder-announces-eptinezumab-significantly-reduces-migraine-risk (accessed 3 February 2018).

Allergan, 2018a. Ubrogepant Achieve II results. Available from: https://www.allergan.com/investors/events-presentations/events/ubrogepant-achieve-ii-results (accessed 08 June 2018).

Allergan, 2018b. Allergan's oral CGRP receptor antagonist atogepant demonstrates robust efficacy and safety in episodic migraine prevention in a phase 2b/3 clinical trial [press release]. Available from: https://www.allergan.com/News/News/Thomson-Reuters/Allergan-s-Oral-CGRP-Receptor-Antagonist-Atogepant (accessed 12 June 2018).

Ashina M, Goadsby P, Silberstein SD, Dodick D, Rippon G, Klatt J et al. Long-term safety and tolerability of erenumab: three-year plus results from an ongoing open-label extension study in episodic migraine. Presented at the 60th Annual Scientific Meeting of the American Headache Society, San Francisco, USA, 28 June – 1 July 2018.

Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol. 2012;8:89–99.

Biohaven Pharmaceutical Holding Company Ltd, 2018. Biohaven announces successful achievement of both co-primary regulatory endpoints in two pivotal phase 3 trials of rimegepant an oral CGRP receptor antagonist for the acute treatment of migraine [press release]. 27 March 2018. Available from: https://www.prnewswire.com/news-releases/biohaven-announces-successful-achievement-of-both-co-primary-regulatory-endpoints-in-two-pivotal-phase-3-trials-of-rimegepant-an-oral-cgrp-receptor-antagonist-for-the-acute-treatment-of-migraine-300619129.html (accessed 27 March 2018).

Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:644–655.

Cady RJ, Shade CL, Cady RK. Advances in drug development for acute migraine. Drugs. 2012;72:2187–2205.

Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–182.

Cho S-J, Song T-J, Min Kyung Chu MK. Treatment Update of Chronic Migraine. Current Pain and Headache Reports. 2017;21:26.

ClinicalTrials,gov. An open-label, long-term, safety study of lasmiditan for the acute treatment of migraine (GLADIATOR). Trial identifier: NCT02565186. Available from: https://clinicaltrials.gov/ct2/show/NCT02565186 (accessed 22 January 2018).

ClinicalTrials.gov. A multicenter assessment of ALD403 in frequent episodic migraine (PROMISE 1). Trial identifier: NCT02559895. Available from: https://clinicaltrials.gov/ct2/show/NCT02559895 (accessed 22 January 2018).

ClinicalTrials.gov. A phase 3, multicenter, randomized, double-blind, placebo-controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine. Trial identifier: NCT02828020. Available from: https://clinicaltrials.gov/ct2/show/NCT02828020 (accessed 22 January 2018).

ClinicalTrials.gov. A study of LY2951742 (galcanezumab) in participants with cluster headache. Trial identifier: NCT02797951. Available from: https://clinicaltrials.gov/ct2/show/NCT02797951 (accessed 3 February 2018).

ClinicalTrials.gov. A study evaluating the effectiveness of AMG 334 injection in preventing migraines in adults having failed other therapies (LIBERTY). Trial identifier: NCT03096834. Available from: https://clinicaltrials.gov/ct2/show/NCT03096834 (accessed 22 January 2018).

ClinicalTrials.gov. A study to evaluate the efficacy and safety of AMG 334 in chronic migraine prevention. Trial Identifier: NCT02066415. Available from: https://clinicaltrials.gov/ct2/show/NCT02066415 (accessed 3 February 2018).

ClinicalTrials.gov. An open label trial of ALD403 (eptinezumab) in chronic migraine. Trial identifier: NCT02985398. Available from: https://clinicaltrials.gov/ct2/show/NCT02985398 (accessed 22 January 20189).

ClinicalTrials.gov. Comparing efficacy and safety of 2 dose regimens of subcutaneous administration of TEV-48125 versus placebo for the preventive treatment of chronic migraine. Trial identifier: NCT02621931. Available from: https://clinicaltrials.gov/ct2/show/NCT02621931 (accessed 22 January 2018).

ClinicalTrials.gov. Efficacy and safety of 2 dose regimens of TEV-48125 versus placebo for the preventive treatment of episodic migraine. Trial identifier: NCT02629861. Available from: https://clinicaltrials.gov/ct2/show/NCT02629861 (accessed 22 January 2018).

ClinicalTrials.gov. Efficacy, safety and tolerability of multiple dosing regimens of oral AGN-241689 in episodic migraine prevention. Trial identifier: NCT02848326. Available from https://clinicaltrials.gov/ct2/show/NCT02848326 (accessed March 2018).

ClinicalTrials.gov. Evaluation of ALD403 (eptinezumab) in the prevention of chronic migraine (PROMISE 2). Trial identifier: NCT02974153. Available from: https://clinicaltrials.gov/ct2/show/NCT02974153 (accessed 22 January 2018).

ClinicalTrials.gov. Evaluation of LY2951742 in the prevention of episodic migraine- the EVOLVE-1 Study (EVOLVE-1). Trial identifier: NCT02614183. Available from: https://clinicaltrials.gov/ct2/show/NCT02614183 (accessed 22 January 2018).

ClinicalTrials.gov. Evaluation of LY2951742 in the prevention of episodic migraine- the EVOLVE-2 Study (EVOLVE-2). Trial identifier: NCT02614196. Available from: https://clinicaltrials.gov/ct2/show/NCT02614196 (accessed 22 January 2018).

ClinicalTrials.gov. Evaluation of LY2951742 in the prevention of chronic migraine (REGAIN). Trial identifier: NCT02614261. Available from: https://clinicaltrials.gov/ct2/show/NCT02614261 (accessed 22 January 2018).

ClinicalTrials.gov. Lasmiditan compared to placebo in the acute treatment of migraine: (SAMURAI). Trial identifier: NCT02439320. Available from: https://clinicaltrials.gov/ct2/show/NCT02439320 (accessed 22 January 2018).

ClinicalTrials.gov. Study to evaluate the efficacy and safety of AMG 334 compared to placebo in migraine prevention (ARISE). Trial identifier: NCT02483585. Available from: https://clinicaltrials.gov/ct2/show/NCT02483585 (accessed January 22 2018).

ClinicalTrials.gov. Study to evaluate the efficacy and safety of AMG 334 in migraine prevention (STRIVE). Trial identifier: NCT02456740. Available from: https://clinicaltrials.gov/ct2/show/NCT02456740 (accessed 22 January 2018).

ClinicalTrials.gov. Three doses of lasmiditan (50 mg, 100 mg and 200 mg) compared to placebo in the acute treatment of migraine (SPARTAN). Trial identifier: NCT02605174. Available from: https://clinicaltrials.gov/ct2/show/NCT02605174 (accessed 22 January 2018). 

ClinicalTrials.gov. A study to evaluate the efficacy and safety of TEV-48125 (fremanezumab) for the prevention of episodic cluster headache (ECH). Trial identifier: NCT02945046. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02945046 (accessed 20 June 2018).

ClinicalTrials.gov. A study comparing the efficacy and safety of TEV-48125 (fremanezumab) for the prevention of chronic cluster headache (CCH). Trial identifier: NCT02964338. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02964338 (accessed 20 June 2018).

ClinicalTrials.gov. A phase 2 study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention. Trial identifier: NCT01952574. Available from: https://clinicaltrials.gov/ct2/show/NCT01952574 (accessed 12 July 2018).

Skljarevski V, Zhang Q, Detke HC, Millen B, Yang J, Selzler KJ et al. Phase 3 study (EVOLVE-2) of galcanezumab in episodic migraine. Presented at the 59th Annual Scientific Meeting of the American Headache Society, Boston, USA, 8-11 June 2017.

Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18(1):96–105.

Detke H. A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study. Presented at the 59th Annual Scientific Meeting of the American Headache Society, Boston, USA, 8-11 June 2017.

Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47:355–363.

Dodick D, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: A phase 3 randomized trial of erenumab for episodic migraine. Cephalagia 2018a; 38(6):1026–1037.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018b;319(19):1999-2008.

Eadie MJ. Ergot of rye-the first specific for migraine. J Clin Neurosci. 2004;11(1):4–7.

Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7:9–14.

Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80(2):193–9.

European Medicines Agency, 2018. First monoclonal antibody therapy for prevention of migraine [press release]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2018/06/WC500249906.pdf (accessed 08 June 2018).

Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know.  Circulation. 2013;127:2222–2230.

Food and Drug Administration, 2018. FDA approves novel preventive treatment for migraine [press release]. 17 May 2018. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608120.htm (accessed 08 June 2018).

Ghelardini C, Di Cesare Mannelli L, Bianchi E. The pharmacological basis of opioids. Clinical Cases in Mineral and Bone Metabolism. 2015;12(3): 219–221.

Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11:1045–1057.

Goadsby PJ. Therapeutic prospects for migraine: can paradise be regained? Ann Neurol. 2013;74:423–434.

Goadsby, PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al., A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377:2123–2132.

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F et al. Sustained efficacy over 1 year of treatment with erenumab: results from the extension phase of the STRIVE study in episodic migraine. Presented at the 60th Annual Scientific Meeting of the American Headache Society, San Francisco, USA, 28 June – 1 July 2018.

See poster here.


Hoffmann J, Goadsby PJ. Emerging targets in migraine. CNS Drugs. 2014;28:11–17.

Katsarava Z, Mania M, Lampl C, Herberhold J and Steiner TJ. Poor medical care for people with migraine in Europe – evidence from the Eurolight study. J Headache Pain 2018;19:1.

Kleinberg M, Mosdell KW. Current and future considerations for the new classes of biologicals. Am J Health Syst Pharm. 2004;61:695–708.

Lanteri-Minet M, Buse D, Starling AJ, Ailani J, Zhang F, Wen S et al. Patient-reported outcomes in chronic migraine patients with prior prophylactic treatment failure receiving placebo or erenumab: subgroup analysis of a pivotal randomised study. Abstract presented at EAN, 17 June 2018, Lisbon, Portugal.

Lilly, 2017a. FDA accepts biologics license application (BLA) to review galcanezumab for the prevention of migraine in adults [press release]. 11 December 2017. Available from: https://investor.lilly.com/news-releases/news-release-details/fda-accepts-biologics-license-application-bla-review (accessed 22 January 2017).

Lilly, 2017b. Lilly announces positive results for second phase 3 study of  lasmiditan for the acute treatment of migraine [press release]. 4 August 2017. Available from: https://www.prnewswire.com/news-releases/lilly-announces-positive-results-for-second-phase-3-study-of-lasmiditan-for-the-acute-treatment-of-migraine-300499684.html (accessed 22 January 2018).

Lilly, 2018. Lilly's galcanezumab meets primary endpoint in Phase 3 study evaluating galcanezumab for the prevention of episodic cluster headache [press release]. 15 May 2018. Available from: https://www.prnewswire.com/news-releases/lillys-galcanezumab-meets-primary-endpoint-in-phase-3-study-evaluating-galcanezumab-for-the-prevention-of-episodic-cluster-headache-300648022.html (accessed 19 June 2018).

Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J. 2005;46:258–268.

Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53:1300–1311.

MacGregor EA, Steiner TJ, Davies PTG. British Association for the Study of Headache Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type, Cluster and Medication-Overuse Headache Writing Committee: 3rd edition (1st revision); approved for publication, September 2010. Available from: https://www.bash.org.uk/wp-content/uploads/2012/07/10102-BASH-Guidelines-update-2_v5-1-indd.pdf (accessed 17 January 2017).

Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20.

McAllister P, Pascual J, McGill L, Newman L, Tassorelli C, Zhang F et al. Efficacy of erenumab for the treatment of patients with episodic migraine with aura. Abstract presented at EAN, 18 June 2018, Lisbon, Portugal.

NICE, 2012. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine Technology appraisal guidance [TA260] Published date: 27 June 2012. Available from: https://www.nice.org.uk/guidance/ta260 (accessed 17 January 2018).

NICE, 2013. Headaches in over 12s Quality standard [QS42] Published date: August 2013. Available from: https://www.nice.org.uk/guidance/qs42/chapter/quality-statement-4-combined-treatment-for-migraine (accessed 17 January 2018).

Novartis, 2016. Novartis announces Phase phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine [press release]. 28 September 2016. Accessed January 17, 2018 at: https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-study-shows-amg-334-significantly-reduces-monthly (accessed 22 January 2018).

Novartis, 2018. Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine [press release]. 28 June 2018. Available from: https://www.novartis.com/news/media-releases/novartis-presents-new-data-demonstrating-long-term-efficacy-safety-and-tolerability-aimovigr-erenumab-patients-chronic-and-episodic-migraine?utm_campaign=2018-06-pr-migraine-data&utm_medium=social&utm_source=linkedin (accessed 12 July 2018).

Obermann M, Holle D Recent advances in the management of migraine. F1000Res. 2016 Nov 21;5:2726.

Ong JJY, Wei DYT, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs. 2018;78:411–437.

Phase 3 STRIVE and ARISE Trials Show Efficacy, Safety for Erenumab in Migraine Prevention. Medscape. at: http://wb.md/2gWxUYg [http://www.medscape.com/viewarticle/879161

Pascual J, Buse D, Starling AJ, Ailani J, Zhang F, Wen S et al. Effect of erenumab on patient-reported outcomes in episodic migraine patients with prior prophylactic treatment failure: results from a post-hoc analysis of the STRIVE study. Abstract presented at EAN, 17 June 2018, Lisbon, Portugal.

Pringsheim T, Becker WJ.Triptans for symptomatic treatment of migraine headache. BMJ. 2014 Apr 7;348:g2285.

Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ. 2010;182:E269–E276.

Raffaelli B, Israel H, Neeb L, Reuter U. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opinion on Pharmacotherapy. 2017;18(13):1409–1415.

Reichert JM. Antibodies to watch in 2016. mAbs. 2016;8:197-204.

Reuter U, Israel H, Neeb L. The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord. 2015;8(1): 46–54.

Reuter U, Goadsby P, Lanteri-Minet M, Ferrari M, Wen S, Klatt J. Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures. Results from the Phase 3b LIBERTY study. Emerging science abstract presented at AAN, 24 April 2018, Los Angeles.

Saper J, Lipton R, Kudrow D, Hirman J, Dodick D, Silberstein S et al. Primary results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) trial: a phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraines. Abstract presented at AAN, 24 April 2018, Los Angeles.

Shahien R, Beiruti K. Preventive Agents for Migraine: Focus on the Antiepileptic Drugs. Journal of Central Nervous System Disease 2012:4 37–49.

Silberstein S, Lenz R, Xu C. Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know. Headache. 2015;55:1171–1182.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2112–22.

Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–762.

Silberstein SD. Preventive Migraine Treatment. Continuum. 2015;21:973–989.

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine. The EVOLVE-1 randomized clinical trial. JAMA Neurology 2018;May 29 [Epub ahead of print].

Stauffer VL, Wang S, Bangs M, Carter J, Aurora SK. Phase-3 safety data form studies comparing galcanezumab and placebo in patients with episodic and chronic migraine. Abstract presented at EAN, 16 June 2018, Lisbon, Portugal.

Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81–88.

Tepper S, Ashina M, Reuter U, Brandes JL, DoleĹžil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425-434.

Teva, 2017. FDA Accepts accepts Biologics License Application for Fremanezumab fremanezumab with Priority priority Review review for Prevention prevention of Migraine migraine and Grants grants Fast fast Track track Designation designation for Cluster cluster Headache headache Development development Program program [press release]. 18 December 18, 2017. Available from: http://www.tevapharm.com/news/fda_accepts_biologics_license_application_for_fremanezumab_with_priority_review_for_prevention_of_migraine_and_grants_fast_track_designation_for_cluster_headache_development_program_12_17.aspx (accessed 22 January 2018).

Teva, 2018a. European Medicines Agency (EMA) accepts fremanezumab marketing authorization application [press release]. 2 February 2018. Available from: https://markets.ft.com/data/announce/detail?dockey=600-201802020700BIZWIRE_USPRX____BW5142-1 (accessed 3 February 2018).

Teva, 2018b. Teva provides update on clinical trial of fremanezumab for use in chronic cluster headache [press release]. Available from: http://www.tevapharm.com/news/teva_provides_update_on_clinical_trial_of_fremanezumab_for_use_in_chronic_cluster_headache_06_18.aspx (accessed 20 June 2018).

Tfelt-Hansen P, Saxena PR, Dahlöf C, Pascual J, Láinez M, Henry P, et al. Ergotamine in the acute treatment of migraine: A review and European consensus. Brain. 2000; 123(1):9–18.

Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain. 2012;13(4):271–5.

Trugman J, Finnegan M, Lipton R, Dodick D, Lu K, Lakkis H, Szegedi A. Efficacy, safety and tolerability of ubrogepant for the acute treatment of migraine: results from a single attack phase III study ACHIEVE I. Emerging science abstract presented at AAN, 24 April 2018, Los Angeles.

Tso AR, Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention. Curr Treat Options Neurol. 2017;19:27–38.

Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, et al., A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–898.

Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol & Therapeutics. 2008;84:548–558.

Wietecha LA, Kuca B, Asafu-Adjei J, Aurora S. Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine. Abstract presented at AAN, 27 April 2018, Los Angeles, 2018a.

Wietecha LA, Kuca B, Case MG, Selzer KJ, Aurora S. Phase-3 study (SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine. Abstract presented at EAN, 19 June 2018, Lisbon, Portugal, 2018b.

Winner P, Reuter U, Dodick D, Kudrow D, Rozniecki J, Xue G et al. Safety of erenumab among patients with migraine using triptans or with cardiovascular risk factors. Abstract presented at EAN, 17 June 2018, Lisbon, Portugal.

Zhang Q, Ruff DD, Pearlman EM, Govindan S, Aurora SK. Efficacy of galcanezumab in patinets who failed to respond to preventives previously: results from EVOLVE-1, EVOLVE-2 and REGAIn studies. Abstract presented at EAN, 16 June 2018, Lisbon, Portugal.

Disease Awareness

Disease Awareness

Discover detailed migraine awareness with/without aura, HALT index, pathophysiology and the trigeminal system, symptoms including visual disturbances and nausea and diagnosis from the International Classification of Headache Disorders 3 (ICHD-3).

Guidelines

Guidelines

National and international guidelines on all aspects of migraine management including the European Headache Federation (EHF), the European Federation of Neurological Sciences (EFNS) and the International Headache Society (IHS).

Glossary

Glossary

Review the terms used in the Migraine Knowledge Centre, along with their definitions including cortical spreading depression, Headache-Attributed Lost Time index (HALT), Hemiplegic migraine and vagus nerve stimulation.

 

Login/ Register Maximise Minimise